International Assets Investment Management LLC Purchases 104,485 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

International Assets Investment Management LLC boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 248,773.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,527 shares of the company’s stock after purchasing an additional 104,485 shares during the quarter. International Assets Investment Management LLC’s holdings in Medpace were worth $32,041,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Riverbridge Partners LLC increased its holdings in shares of Medpace by 7.1% during the fourth quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock worth $199,975,000 after purchasing an additional 43,197 shares during the period. Invesco Ltd. grew its position in Medpace by 67.6% during the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after buying an additional 246,775 shares in the last quarter. Wellington Management Group LLP raised its holdings in Medpace by 312.6% in the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after acquiring an additional 319,210 shares in the last quarter. Northern Trust Corp raised its holdings in Medpace by 4.0% in the 3rd quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock valued at $58,402,000 after acquiring an additional 9,192 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Medpace by 55.7% during the 3rd quarter. AQR Capital Management LLC now owns 183,310 shares of the company’s stock valued at $44,385,000 after acquiring an additional 65,614 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their price target for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Robert W. Baird boosted their price objective on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, Guggenheim raised their target price on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $443.00.

Medpace Trading Up 0.4 %

Shares of Medpace stock opened at $392.57 on Friday. The firm’s 50 day moving average is $398.08 and its 200 day moving average is $330.45. The firm has a market capitalization of $12.16 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 1.98 and a beta of 1.40. Medpace Holdings, Inc. has a 1 year low of $197.39 and a 1 year high of $421.00.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter in the previous year, the firm posted $2.27 earnings per share. The company’s revenue was up 17.7% on a year-over-year basis. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of Medpace stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the sale, the insider now directly owns 5,525,959 shares of the company’s stock, valued at $2,135,175,298.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Medpace news, major shareholder Medpace Investors, Llc sold 13,988 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the transaction, the insider now directly owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The disclosure for this sale can be found here. Insiders sold a total of 204,442 shares of company stock valued at $82,702,867 in the last 90 days. Corporate insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.